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Pharmacokinetic comparisons of S-oxiracetam
and R-oxiracetam in beagle dogs
A pharmacokinetic comparison and conformational stability 
study of S-oxiracetam (S-ORT) and R-oxiracetam (R-ORT) in 
beagle dogs was used to investigate the possible mechanism 
of different effects of two oxiracetam enantiomers through a 
random crossover design. After drug administration to beagle 
dogs, blood samples were collected at different time points 
for pharmacokinetic analysis using the UPLC-ESI-MS/MS 
method. Parts of plasma samples were used for conformation 
transformation studies using a normal phase high perfor-
mance liquid chromatographic (NP HPLC) method. The 
study showed that oxiracetam enantiomers maintained their 
original conformation when administered orally to beagle 
dogs. Concentrations of S-ORT were significantly higher 
than R-ORT 1.5 and 2 h after administration; the AUC0-∞ of 
S-ORT after oral administration tended to be higher than 
that of R-ORT, which showed that the different effects 
between S-ORT and R-ORT may be partly associated with 
their distinctive absorption at least.
Keywords: S-oxiracetam, R-oxiracetam, conformation, phar-
macokinetics, beagle dogs
Oxiracetam (4-hydroxy-2-oxo-1-pyrrolidine acetamide, ORT) is a derivative of pirace-
tam. As a nootropic agent, oxiracetam can improve both learning and memory processes 
and is used in the treatment of various cognitive disorders (1–4). ORT is a chiral drug; at 
present, the form of ORT used in clinical treatment is a racemate (Fig. 1).
It is well known that chirality is a basic characteristic of biological systems. Major 
components of a biological system, such as carbohydrates, proteins, amino acids and lip-
ids, all exhibit chirality. These components are closely related to intracorporeal character-
istics of drugs, such as absorption, distribution, metabolism, and excretion (5–9). Two dif-
ferent enantiomers may exhibit different pharmacological effects as well as different 
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Two enantiomers of oxiracetam exhibit different pharmacological effects, as well. It 
was demonstrated that the S enantiomer of oxiracetam is more active than the R enantio-
mer in inducing long term potentiation (LTP) in the rat hippocampal slices in vitro, in po-
tentiating glutamate-stimulated Ca2+ uptake in cultured cerebellar granule cells and in 
reverting the scopolamine induced amnesia in rats (13), suggesting that admistration of 
S-ORT would be therapeutically beneficial.
Differences in enantiomer effects may also occur from the pharmacokinetic aspect. 
Two enantiomers may show different pharmacokinetic features owing to their different 
spatial structure. Whether there were any pharmacokinetic differences between the two 
enantiomers of oxiracetam was not reported so far. In this paper, we carried out compara-
tive pharmacokinetic studies of S-ORT and R-ORT in beagle dogs after studying the 
stereochemical stability of ORT enantiomers using a chiral separation column.
EXPERIMENTAL
Chemicals and reagents
ORT enantiomers (purity > 98 %) were provided by Chongqing Dongze Pharmaceuti-
cal Science and Technology Co. Ltd. (China), and piracetam (internal standard, IS) was 
purchased from the National Institute for the Control of Pharmaceutical and Biological 
Products (China). High-performance liquid chromatography (HPLC)-grade n-hexane was 
supplied by Tedia (USA). All other chemicals and solvents used were of analytical grade. 
The purity of all chemicals was above 99.9 %.
Animals
Six beagle dogs (3 males and 3 females), weighing 13.67 ± 2.04 kg and 6.3 ± 2.1 months 
of age, were purchased from the Shanghai Institute of Xingang Experimental Animal Cen-
ter (China). All animal studies were approval by the Yijishan Hospital Ethics Committee 
(Wuhn PRC) and were carried out according to the Guide for Care and Use of Laboratory 
Animals of Yijishan Hospital.
Dogs were housed with unlimited access to food and water, but were fasted 12 h be-
fore the experiment. The animals were kept under a 12:12-h light-dark cycle (lights on from 
8:00 to 20:00 h) at ambient temperature (22–24 °C) and 60 % relative humidity.
Fig. 1. Chemical structures of: a) S-oxiracetam and b) R-oxiracetam.
a)                                                     b)                                                 
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Study design
A random crossover experimental design was implemented to study conformational 
stability and pharmacokinetic differences between S-ORT and R-ORT in beagle dogs. Six 
dogs were divided into 2 groups. Dogs in the first group were given S-ORT (50 mg kg-1, 
administered orally), while dogs in the other group were given R-ORT (50 mg kg-1, admin-
istered orally). After a 1-week washout period, dogs in each group were switched and re-
ceived the other drug.
After drug administration, 3 mL anticoagulant blood samples were collected from 
forelimb veins at 0, 0.08, 0.25, 0.5, 0.75, 1, 1.5, 2, 4, 6, 8, 12, 16, and 24 h. Blood samples were 
centrifuged at 4000 rpm for 5 min immediately after collection to separate plasma and 
were stored at −70 °C until analysis.
Portions of the plasma samples of S-ORT and R-ORT collected at 0, 1, 1.5, and 2 h after 
oral administration were used for transformation studies. Plasma samples were used for 
pharmacokinetic analysis at all time points.
Enantiomer transformation
HPLC. – ORT enantiomers were separated using a Waters (USA) HPLC system equipped 
with a binary pump (1525), CTO-10Asvp thermostated column oven, 717 plus auto-sam-
pler, and 2487 UV detector. Chromatographic separation was performed on a Chiralel OC 
Daicel (4.6 × 250 mm) column. The isocratic mobile phase, a mixture of hexane-ethanol 
(75:25, V/V), was delivered at 1.0 mL min-1. The temperature of the column was maintained 
at 30 °C, the detection wavelength was 210 nm and the injected volume was 50 μL. The 
chromatographic run time for each sample was 35 min.
Samples and standards. – Five hundred microliters of methanol and 500 μL plasma were 
vortexed for 3 min. Then, 10 mL ethyl acetate was added into the mixture and vortexed for 
5 min. The tubes were centrifuged at 15,000 rpm at 4 °C for 10 min. Supernatants (9 mL) 
were enclosed in a thermostatic water bath at 38 °C and dried with nitrogen. After drying, 
100 μL of mobile phase solution was added. The tubes were then centrifuged at 15,000 rpm 
at 4 °C for 10 min again. Supernatants (80 μL) were pipetted into autosampler vials, 50 μL 
of which was injected into the column for analysis.
S-ORT and R-ORT, at three concentrations of 10, 50, and 100 μg mL–1, were used as 
quality control (QC) samples. Intra-day precision was tested by analysis of QC samples (n 
= 6 each) at 5 different times in the same day. Interday precision (n = 6 each) was deter-
mined by repeated analyses of the same samples over 5 consecutive days. Precision was 
determined as relative standard deviation of peak areas.
Pharmacokinetics
HPLC. – S-ORT and R-ORT concentrations were measured using a sensitive and specific 
ultra performance liquid chromatography-electrospray ionization-tandem mass spectrom-
etry (UPLC-ESI-MS/MS) method. A Shimadzu (Japan) LC system equipped with a binary 
pump (LC-20AD), vacuum degasser (DGu-20A5), CTO-10Asvp thermostated column oven 
and an SIL-HTc autosampler were used. Chromatographic separation was performed on an 
HP Amide LC-MS/MS column (100 mm × 3.00 mm, 5 μm). The isocratic mobile phase, a 
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mixture of methanol-water (85:15, V/V), was delivered at 0.2 mL min–1. Piracetam was used 
as an internal standard (IS). The temperatures of the column and autosampler were main-
tained at 40 and 4 °C, respectively. The chromatographic run time for each sample was 5 
min. Detection was located in the positive ion mode with multiple reaction monitoring (mass 
transition [m/z] 159.0®114.1 and 143.0®126.1 for ORT and piracetam).
Samples and standards. – Plasma samples were added to an Eppendorf tube spiked with 
IS working solution (piracetam). Samples were extracted with methanol and then centri-
fuged, and supernatants were pipetted into an autosampler vial for analysis. Duplicate QC 
samples at 3 concentration levels spanning the assay range (low, medium, and high) were 
included in each analytical run to measure assay performance. Analyses were performed 
within a concentration range of 0.05–50 μg mL–1 for both enantiomers (14). Inter-assay 
precision and accuracy were determined using QC samples from all study sample runs.
Pharmacokinetic analysis and statistics
Transformations of the enantiomers were calculated by determining the peak area 
ratio of S-ORT to R-ORT.
The relationship of time versus plasma concentration for S-ORT and R-ORT was ana-
lyzed using a Drug and Statistics computer program (version 1.0, Mathematical Pharma-
cology Professional Committee of China, Shanghai, China), using a weighted least squares 
regression analysis. Compartment model selection was based on the Akaike Criterion. The 
AUC0-∞ was determined using the linear trapezoidal rule. The pharmacokinetic parame-
ters and mean plasma concentrations were reported as mean ± SD and compared by Stu-
dent’s t-test using the Drug and Statistics computer program (version 1.0, Mathematical 
Pharmacology Professional Committee of China, Shanghai, China). The differences were 
considered to be significant when p-values were less than 0.05.
RESULTS AND DISCUSSION
The pharmacokinetics of ORT in humans and rats has been reported in previous stud-
ies (15–18). As mentioned above, the form of ORT used in clinical treatment is a racemate 
of S-ORT and R-ORT. Previous pharmacodynamic studies have shown that S-ORT was 
the superior isomer (13). But until now no reports have described the pharmacokinetic 
differences between S-ORT and R-ORT. Because in some chiral drugs the enantiomers may 
be transformed into each other, the premise of our pharmacokinetic comparison was to 
determine whether S-ORT could be transformed into R-ORT in vivo. Thus, enantiomer 
transformation studies were necessary and critical. As the UPLC-ESI-MS/MS method 
could not separate enantiomers, we developed a normal phase high performance liquid 
chromatographic (NP-HPLC) method for chiral separation of ORT enantiomers in beagle 
dog plasma to study conformational transformation.
Separation of ORT enantiomers
The NP-HPLC method was developed for chiral separation of ORT enantiomers in 
beagle dogs’ plasma to study conformational stability. Under the current chromatographic 
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conditions, the retention times of R-ORT and S-ORT were 23.3 and 26.2 min, respectively 
(Fig. 2). No endogenous interference was detected at the retention time of the peaks. 
The degree of separation was 1.2, the theoretical plate number was 3310 m–1, which was 
Fig. 2. NP-HPLC chromatograms of: a) blank dog plasma, b) blank dog plasma spiked with ORT 
 racemate (10 μg mL–1), c) blank dog plasma spiked with S-ORT (10 μg mL–1), d) blank dog plasma 
spiked with R-ORT (10 μg mL–1), e) plasma sample 1.5 h after oral administration of S-ORT (50 mg kg–1), 
and f) plasma sample 1.5 h after oral administration of R-ORT (50 mg kg–1).









e)                                                                               f)
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calculated for S-ORT (Table I). Intra- and inter-day precision and accuracy are presented 
in Table II. The results showed acceptable precision and accuracy of the analyses in dog 
plasma samples. At all the 3 concentrations (10, 50 and 100 μg mL–1), the peak area was 
linear in relation to its concentration in the concentration range 5–150 μg mL–1.
Stereochemical stability of ORT enantiomers
After intragastric administration of S-ORT and R-ORT at the chosen time points, the 
mean peak area ratio of R-ORT to S-ORT was 0.025 and that of S-ORT to R-ORT was 0.019. 
This indicated that only ca 2 % of ORT was converted in beagle dogs, which could be 
ignored. This result shaped our pharmacokinetic study of S-ORT.
Pharmacokinetic differences between S-ORT and R-ORT in beagle dogs
Because the sensitivity of NP-HPLC could not satisfy the requirements of pharmaco-
kinetic research, we chose the UPLC-ESI-MS/MS method, which was already established 
in our laboratory (14). Due to the facts that the UPLC-ESI-MS/MS method could not sepa-
rate the enantiomers and that the enantiomers did not transform into each other, this 
method seems to be appropriate for pharmacokinetic studies.
The time-concentration curves of S-ORT and R-ORT are depicted in Fig. 3. Both S-ORT 
and R-ORT concentration-time data after oral administration were best fitted as one-com-










S-ORT 9.93 1.01 26.2
1.12 1.20
R-ORT 8.76 0.98 23.3
Table II. Precision and accuracy for determination of R-ORT and S-ORT in dog plasma by the NP-HPLC 
method









S-ORT 10.00 10.97 ± 0.81 4.3 8.4 9.7
50.00 51.23 ± 3.51 2.2 6.8 2.5
100.00 106.37 ± 9.75 4.0 6.1 6.4
R-ORT 10.00 10.85 ± 0.84 5.1 9.0 8.5
50.00 51.62 ± 3.67 2.6 6.9 3.2
100.00 109.10 ± 9.99 2.6 8.1 9.1
a Mean ± SD, n = 5.
b n = 5.
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partment open models. In Fig. 3, at 1.5 and 2 h after administration, the S-ORT concentration 
was significantly higher than that of R-ORT (p < 0.05).
The pharmacokinetic parameters are given in Table III. The elimination half-life (t1/2), 
mean resident time (MRT), absorption half-life (t1/2ka), peak time (tmax), volume of distribu-
tion (Vd), and systemic clearance (Cl) of S-ORT were all similar to those of R-ORT after oral 
administration. In contrast, the AUC0-∞ of S-ORT after oral administration tended to be 
higher than that of R-ORT (p < 0.05). Having in mind the equation AUC0-∞ = FD/Cl, one can 
Fig. 3. Mean plasma concentration vs. time profiles in 6 dogs after intragastric administration of a 
single 50 mg kg-1 dose of S-ORT and R-ORT. Each point and bar represent mean ±SD, n = 6.
Table III. Pharmacokinetic parameters of S-ORT and R-ORT given orally to beagle dogsa 
Parameter S-ORT R-ORT
t1/2 (h) 3.33 ± 0.63 3.11 ± 0.63
t1/2ka (h)b 0.64 ± 0.33 0.51 ± 0.42
Vd (L kg–1) 4.09 ± 2.34 5.06 ± 2.44
Cl/F (L h–1 kg–1) 0.89 ± 0.39 1.07 ± 0.61
AUC0-∞ (mg L–1 h–1) 110.77 ± 19.69c 86.43 ± 14.97
MRT 0-∞ (h) 4.62 ± 0.66 4.65 ± 0.87
tmax (h) 1.33 ± 0.26 1.79 ± 1.17
cmax (mg L–1) 31.15 ± 10.82 23.10 ± 12.31
a Dose: 50 mg kg–1, mean ± SD, n = 6.
b Absorption half time.
c Significantly different from R-ORT (p < 0.05).
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speculate that in the case of AUC changes, Cl and F are parameters that can interfere as-
suming the same dose. As there are no significant differences in Cl and t1/2, we can con-
clude that parameter F, which depicts the extent of absorption, is significantly higher in the 
case of S-form. Moreover, this conclusion is supported by the fact that cmax of S-ORT tends 
to be significantly higher than cmax of R-ORT. Many reasons can lead to different absorp-
tion, such as the different destruction degree of the two enantiomers in the gastrointestinal 
tract, the different binding capacity to transporters, and so on. The exact reasons for different 
absorption of the two enantiomers of ORT need to be further studied.
As mentioned above, concentration of S-ORT was significantly higher than that of 
R-ORT 1.5 and 2 h after administration, and the AUC0-∞ of S-ORT after oral administration 
tended to be higher than that of R-ORT, indicating that the absorption rate of S-ORT was 
higher than that of R-ORT. According to the classical theory of pharmacology, higher 
absorption and higher concentration result in stronger effects. This result showed that the 
different effects of S-ORT and R-ORT (13) may be partly associated with their distinctive 
absorption at least. Other pharmacokinetic parameters of S-ORT after oral administration 
were very similar to those of R-ORT, which indicates that there were no significant differ-
ences in intracorporeal processes such as distribution, metabolism and excretion.
CONCLUSIONS
In this study, only ca 2 % of ORT enantiomers were converted to each other (S-ORT 
and R-ORT), which indicated that ORT enantiomers were well maintained in their original 
conformations in beagle dogs. There were significant differences in absorption between 
the two enantiomers of oxiracetam, which may resulted in different pharmacological 
effects. The reasons for different absorption of the two enantiomers need to be further 
studied.
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